Combination of Cladribine and Cytarabine is Effective for Childhood Acute Myeloid Leukemia: Results of the St. Jude AML97 Trial

[1]  C. Pui,et al.  Prophylactic antibiotics reduce morbidity due to septicemia during intensive treatment for pediatric acute myeloid leukemia , 2008, Cancer.

[2]  S. Feig,et al.  Outcomes in CCG-2961, a children's oncology group phase 3 trial for untreated pediatric acute myeloid leukemia: a report from the children's oncology group. , 2008, Blood.

[3]  T. Alonzo,et al.  Microbiologically documented infections and infection-related mortality in children with acute myeloid leukemia. , 2007, Blood.

[4]  D. Reinhardt,et al.  Less toxicity by optimizing chemotherapy, but not by addition of granulocyte colony-stimulating factor in children and adolescents with acute myeloid leukemia: results of AML-BFM 98. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  F. Behm,et al.  children with AML in remission : Pediatric Oncology Group Study 9421 Randomized use of cyclosporin A ( CsA ) to modulate P-glycoprotein in , 2005 .

[6]  U. Creutzig,et al.  Pediatric acute myeloid leukemia: international progress and future directions , 2005, Leukemia.

[7]  R. Hills,et al.  Treatment strategy and long-term results in paediatric patients treated in consecutive UK AML trials , 2005, Leukemia.

[8]  D. Reinhardt,et al.  Early deaths and treatment-related mortality in children undergoing therapy for acute myeloid leukemia: analysis of the multicenter clinical trials AML-BFM 93 and AML-BFM 98. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  C. Pui,et al.  Phase II trial of cladribine and cytarabine in relapsed or refractory myeloid malignancies. , 2004, Leukemia research.

[10]  D. Reinhardt,et al.  Infectious complications in pediatric acute myeloid leukemia: analysis of the prospective multi-institutional clinical trial AML-BFM 93 , 2004, Leukemia.

[11]  J. Downing,et al.  Clinical significance of residual disease during treatment in childhood acute myeloid leukaemia , 2003, British journal of haematology.

[12]  G. Gustafsson,et al.  Treatment stratification based on initial in vivo response in acute myeloid leukaemia in children without Down's syndrome: results of NOPHO‐AML trials , 2003, British journal of haematology.

[13]  Deo Kumar Srivastava,et al.  Interim comparison of a continuous infusion versus a short daily infusion of cytarabine given in combination with cladribine for pediatric acute myeloid leukemia. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  S. Raimondi,et al.  Experience with 2-chlorodeoxyadenosine in previously untreated children with newly diagnosed acute myeloid leukemia and myelodysplastic diseases. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  T. Robak,et al.  Combination Regimen of Cladribine (2-Chlorodeoxyadenosine), Cytarabine and G-CSF (CLAG) as Induction Therapy for Patients with Relapsed or Refractory Acute Myeloid Leukemia , 2000, Leukemia & lymphoma.

[16]  R. Gray,et al.  Marked improvements in outcome with chemotherapy alone in paediatric acute myeloid leukaemia: results of the United Kingdom Medical Research Council's 10th AML trial , 1998 .

[17]  R. Gray,et al.  Marked improvements in outcome with chemotherapy alone in paediatric acute myeloid leukemia: results of the United Kingdom Medical Research Council's 10th AML trial. MRC Childhood Leukaemia Working Party. , 1998, British journal of haematology.

[18]  E. Estey,et al.  Clinical and laboratory studies of 2-chlorodeoxyadenosine +/- cytosine arabinoside for relapsed or refractory acute myelogenous leukemia in adults. , 1996, Leukemia.

[19]  E. Estey,et al.  Chlorodeoxyadenosine and arabinosylcytosine in patients with acute myelogenous leukemia: pharmacokinetic, pharmacodynamic, and molecular interactions. , 1996, Blood.

[20]  R. Krance,et al.  Complete hematologic remissions induced by 2-chlorodeoxyadenosine in children with newly diagnosed acute myeloid leukemia. , 1994, Blood.

[21]  M. Story,et al.  Induction of apoptotic cell death in chronic lymphocytic leukemia by 2-chloro-2′-deoxyadenosine and 9-β-D-arabinosyl-2-fluoroadenine , 1993 .

[22]  M. Story,et al.  Induction of apoptotic cell death in chronic lymphocytic leukemia by 2-chloro-2'-deoxyadenosine and 9-beta-D-arabinosyl-2-fluoroadenine. , 1993, Blood.

[23]  M. Schell,et al.  2-Chlorodeoxyadenosine produces a high rate of complete hematologic remission in relapsed acute myeloid leukemia. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  M. Schell,et al.  A phase I clinical trial of 2-chlorodeoxyadenosine in pediatric patients with acute leukemia. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  D. Carson,et al.  Potent toxicity of 2-chlorodeoxyadenosine toward human monocytes in vitro and in vivo. A novel approach to immunosuppressive therapy. , 1990, The Journal of clinical investigation.